Back to Results

Study to Investigate DSTA4637S in Participants With Staphylococcus Aureus Bacteremia

Title Study to Investigate the Safety, Tolerability, and Pharmacokinetics of DSTA4637S in Participants With Staphylococcus Aureus Bacteremia Receiving Standard-of-Care (SOC) Antibiotics
Therapeutic Area Blood Stream Infection, MRSA, Staphylococcus aureus
Principal Investigator Yoav Golan, MD
Min Age 18 Years
Max Age 75 Years
Gender All
Contact Deirdre Burke
617 636-3665
More Information


The purpose of this study is to test the safety of DSTA4637S, an investigational drug, at different dose levels and to find out what effects, good or bad, DSTA4637S, has on you while treating the S. aureus infection in your blood. DSTA4637S will be given in addition to the antibiotics you are already receiving for your S. aureus infection.

DSTA4637S is an investigational antibiotic to treat serious infections caused by the bacteria S. aureus. DSTA4637S is an experimental drug, which means that the Food and Drug Administration (FDA) or other health authorities that regulate new drugs have not approved DSTA4637S for the treatment of S. aureus bacteremia, except for testing in clinical trials.

Study Details

Inclusion Criteria

  • positive blood culture for S. aureus.
  • Expected treatment with anti-staphylococcol standard of care antibiotics for at least 4 weeks.
  • Body Mass Index between 18 to 32 kg/m2

Exclusion Criteria

  • Known rifampicin resistant S. aureus bacteremia.
  • Pregnancy/breast feeding.
  • Presence of an intravascular catheter not planned to be removed.

Study Requirements